ArriVent BioPharma and Allist Pharmaceuticals unveiled groundbreaking data from their global Phase Ib proof-of-concept randomized study (FURTHER) at the IASCLC 2024 WCLC.

Competing in the $40 Billion Alopecia Areata Market: Hengrui's JAK1 Inhibitor Ivarmacitinib Receives Approval for New Indication Application.

B7-H3 (also known as CD276) is a type I transmembrane glycoprotein and a member of the B7 family.

Grünenthal announced the acquisition of the American pharmaceutical manufacturer Valinor Pharma for $250 million in order to obtain the rights to Movantik (naloxegol).

Zealand Pharma and Boehringer Ingelheim (BI) announced breakthrough clinical trial results for Survodutide, a novel drug targeting metabolic dysfunction-associated steatohepatitis (MASH).

September 5, the NMPA Center for Drug Evaluation (CDE) announced that the clinical trial application (IND) for SKB571, an injectable drug from Kelun-Biotech, has been accepted.

LENZ Therapeutics, a biopharmaceutical company dedicated to developing the first and only eye drop based on aceclidine (LNZ100) to improve near vision in presbyopia patients.

Bispecific antibodies (commonly abbreviated as BsAbs) are an innovative class of biological drugs capable of simultaneously binding to two different antigens or epitopes.

The launch of the bispecific DLL3/CD3 antibody Tarlatamab marks a significant turning point for targeting DLL3.

at the ESC Congress, Bayer published the pooled analysis of the Phase III FINE-HEART study on finerenone, along with the latest data from the FINEARTS-HF trial.

Antibody-Drug Conjugates (ADCs), as a part of precision medicine, target tumor cells by combining the specificity of antibodies with the potent effects of cytotoxins.

NewBridge will have exclusive distribution rights in Algeria, Iraq, Libya, and Jordan for CRYSVITA® (burosumab) for the treatment of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO).